Clinical development company TVAX Biomedical revealed on Thursday that it has received the US Food and Drug Administration's (FDA) fast track designation to accelerate the marketing approval of its vaccine-enhanced adoptive T cell therapy (VACT) for the treatment of glioblastoma multiforme (GBM), a deadly form of brain cancer.
The company has completed Phase 1 and 2a studies in GBM. Significant benefit was demonstrated in GBM patients using TVAX's patented VACT in those studies.
Planned studies will evaluate VACT in newly diagnosed GBM patients who have healthy immune systems and minimal disease at a time when VACT would be anticipated to generate maximal efficacy.
TVAX is seeking investors and corporate alliances to support the development of its lead candidate.
FDA grants Priority Review to Genentech's Enspryng for MOGAD
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
BioEdge Research Labs advances transparency in research compound documentation
Insilico Medicine doses first patient in Phase III trial of rentosertib
BridgeBio reports exploratory PROPEL 3 data showing wider clinical trends for oral infigratinib
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year